Microbiology Culture Market: Alarming Rise in Prevalence of Infectious Diseases a Major Factor Boosting Growth
According to a report by Transparency Market Research, the global microbial culture market is projected to expand at a 5.90% CAGR from 2015 to 2023, rising from a value of US$4.5 bn in 2014 to US$7.5 bn in 2023.
Browse Full Report: http://www.transparencymarketresearch.com/microbiology-culture-market.html
Demand for Improved Antibiotics a Leading Driving Force
The global microbiology culture market is driven by a number of factors, the primary one being increasing demand for improved antibiotics, which has been brought on by the alarming rise in prevalence of infectious diseases and food-borne diseases. According to the Centers for Disease Control and Prevention (CDC), an estimated 23.6 million visits were made to physician offices in 2010 for infectious and parasitic diseases. According to Johns Hopkins, the most common infectious diseases include common cold, Lyme disease, mumps, influenza, HIV/AIDS, severe acute respiratory syndrome (SARS), whooping cough, tuberculosis, and salmonella infections. Tuberculosis has presently infected one-third of the global population, with almost 10,000 new cases reported in the US alone in 2012. foodborne trematodiases, as per the World Health Organization, affected at least 56 million people across the globe in 2005, killing more than 7000. Food-borne trematodiases results from the consumption of raw or poorly cooked food or vegetables harboring the parasite larvae.
Other factors that fuel the microbiology culture market include growing food microbiology, growing food safety concerns, growing lifescience research funding, rise in public awareness and press coverage, evolving pathogens, increase in number of food recalls, and surge in food sourcing resulting from escalating demand for food.
Relief for Sufferers of Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis are largely caused by abnormal immune responses and other issues related to intestinal epithelial cells, gut microbiome, the gut’s rhythmic peristalsis motions, and immune components. Until now, scientists found it difficult to develop new IBD treatment therapies because replicating the microenvironment of the human gut in the lab was extremely complex.
However, last month, a team of researchers at Harvard University’s Wyss Institute for Biologically Inspired Engineering developed a model of human gut inflammation and bacterial overgrowth in what is being called a “human-gut-on-a-chip”. This advance enables scientists, for the first time, to study how normal gut pathogenic bacteria and microbes impact immune responses. This will also allow them to analyze the intestinal physiology in a controlled environment.
Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/microbiology-culture-market.htm
Advancements such as these are another reason why the global microbiology culture market presents massive scope for further growth. Reaping the benefits of these technological and scientific advancements are companies such as Scharlab S.L., Sigma-Aldrich Co. LLC, Hi-Media Laboratories Pvt. Ltd., Bio-Rad Laboratories, Inc., EMD (Merck) Millipore, bioMérieux S.A., Eiken Chemical Co, Ltd., Thermo Fisher Scientific, Inc., Neogen Corporation, and Becton, Dickinson and Company.